Chinese Medtech has "Come of Age"
- More than 250 MedTech companies originating from China listed over the last 5 years
- Multiple billion-dollar Chinese MedTech players with world-class regulatory and manufacturing capabilities and global aspirations
- Chinese players have moved up to developing high-end innovative products for premium markets
- Regulatory reforms accelerate innovative product launches
Major market correction
- Significant market correction over last 12 months (in line with Western markets)
- Investment in BD capabilities and increased caution to secure better deals in this new environment
Solid fundamentals for outstanding value creation in the long run
- solid fundamentals for outstanding value creation:
- a middle class of 500 million people that keeps growing
- an aging society with 31% of Chinese population above 65 years old by 2025
- a National Medical Insurance now covering 100% of the population
- Wide talent base with 250’000 life sciences returnees
- Fast healthcare policy & registration reforms
- Strong financial support of the Chinese government
- lower cost of clinical trials and faster enrollment contributing to a sustainable competitive advantage in medical R&D
How can you take advantage of what's happening in China?
As a US, European or Israeli medical device company, you wonder what you could achieve through a China deal.
You know that the road to the Chinese market is full of obstacles and dead ends. The cultural gap is wide enough to fall into, as many Western companies have already experienced.
Shall you set up your own entity there, or find that outstanding partner with which to build a Joint-Venture or strike a license deal?
How MAVIE can help you?
MAVIE Technologies is a boutique investment bank dedicated to Chinese-Western Medical Device transactions.
We help our clients secure non-dilutive and dilutive financing from strategic and financial Chinese players, working to maximize deal value and certainty. Our team combines deal structuring experience in M&A, equity placement, licensing or joint-venture - with deep Chinese healthcare insights, strategic thinking and privileged access. We add unique value in visualizing, negotiating, and closing the deal.
Our team gathers a unique combination of deep China healthcare insights, M&A experience and medtech vision.